Vertex Pharmaceuticals Incorporated
Clinical trials sponsored by Vertex Pharmaceuticals Incorporated, explained in plain language.
Biopharmaceutical company focused on cystic fibrosis and other serious diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants? Results expected Sep 2026 (estimated)
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug Results expected Oct 2026 (estimated)
- New triple therapy shows promise for cystic fibrosis in Long-Term trial Results expected Oct 2026 (estimated)
- New CF drug candidate VX-581 begins first human safety tests Results expected Nov 2026 (estimated)
- Gene study aims to unlock secrets of kidney disease Results expected Dec 2026 (estimated)
-
Can a pill replace the liquid? testing a new form of cystic fibrosis drug
Disease control Not yet recruitingResearchers are testing whether a tablet form of the experimental cystic fibrosis drug VX-581 gets into the bloodstream as well as the liquid form. Sixteen healthy adults will take both forms in a randomized order, and researchers will measure drug levels in their blood over time…
Phase 1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new injection slow kidney damage in IgA nephropathy?
Disease control Not yet recruitingThis trial tests the long-term safety and effectiveness of povetacicept, an investigational drug given as a subcutaneous injection, in adults with immunoglobulin A nephropathy (IgAN), a kidney disease that can lead to kidney failure. Participants who completed the earlier parent …
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Will a kidney disease drug alter birth control?
Knowledge-focused Not yet recruitingThis phase 1 study tests whether VX-407, an experimental drug for polycystic kidney disease, changes how combined oral contraceptives are processed in the body. Healthy women will take VX-407 alongside different birth control pills, and researchers will measure hormone levels in …
Phase 1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC